ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • Perspectives

    Badulescu CI, Marlowe RJ, Piciu A, Buiga R, Barbos O, Bejinariu NI, Chereches G, Barbus E, Bonci EA , Piciu D

    Circulating Tumor Cells in Minimally Invasive Follicular Thyroid Carcinoma and Benign Thyroid Tumors with a Follicular Pattern: Pilot Experience

    Acta Endo (Buc) 2018 14(1): 1-10 doi: 10.4183/aeb.2018.1

    Abstract
    Purpose. Minimally invasive follicular thyroid carcinomas (MIFCs) are uncommon; literature offers limited guidance on their natural history and management. Starting January 2015 we measured circulating tumor cells (CTCs) in patients with MIFC (n=22) or benign thyroid tumors with follicular features (n=4). Methods. In a retrospective analysis, we assessed detectability of and serial changes in CTC, compared demographic/clinical differences between CTC-positive versus CTC-negative subgroups using Student’s t-test, and examined correlations between CTC status and serum thyroglobulin using Spearman’s test. CTCs were quantitated via immunomagnetic separation/microscopic inspection. Results. Thirteen patients (50%: 12/22 MIFC, 1/4 benign tumor) were initially CTC-positive; 3 remained CTC-positive in ≥1 subsequent measurement. CTC-positive patients had larger tumors and more frequent multifocality and vascular invasion versus CTC-negative patients (n=13). However, no tested variable differed significantly between the subgroups. After 17.2±10.5 months, neither subgroup showed evidence of disease. Significant correlation was absent (p ≥ 0.263) between CTC and Tg negativity (r = 0.243; n=13 evaluable) or initial CTC positivity and Tg positivity (r = -0.418; n=9 evaluable). Conclusions. In the studied settings, CTC measurement is feasible, has unclear clinical/outcome implications, but may provide different information versus thyroglobulin testing. Lengthier assessment is warranted in larger series.
  • General Endocrinology

    Piciu D, Irimie A, Duncea I, Popita V, Straciuc O, Pestean C, Piciu A, Bara A

    Positron emission tomography - computer tomography fusion image, with 18-fluoro-2-deoxyD-glucose in the follow-up of patients with differentiated thyroid carcinoma

    Acta Endo (Buc) 2010 6(1): 15-26 doi: 10.4183/aeb.2010.15

    Abstract
    Aim. The aim of this study is to present the personal experience of the authors regarding the use of positron emission tomography-computer tomography fusion image (PET/CT), with 18Ffluoro-2-deoxy-D-glucose (FDG), in the follow-up of differentiated thyroid carcinoma (DTC).\r\nPatients and Methods. Twenty seven cases of DTC admitted and treated in the “Prof. Ion Chiricu??” Institute of Oncology Cluj-Napoca (IOCN), performed PET/CT investigation\r\nbetween 2007 and 2009, in DOTE Centre Debrecen (Hungary) and Pozitron Center Oradea (Romania). The patients underwent the surgical intervention and had histology of differentiated carcinoma; they received radioiodine therapy with I-131, had suppression therapy with thyroid hormones and had in the follow-up whole body scans (WBS) with I-131, neck ultrasound and serological determination of thyroglobulin (Tg) and anti-thyroglobulin antibodies (anti-Tg). All patients were referred to PET/CT after radical treatment, after a negative WBS I-131 and a dynamic increase of the serological level of Tg or anti-Tg, without any clinical signs of\r\nrecurrence and no neck ultrasound pathological findings.\r\nResults. All patients included in this study presented abnormal levels of Tg: between 2.76 ng/ml and 4173 ng/ml, with a median value of 43.15 ng/ml. In 23 cases (85.1%) the PET/CT results revealed the neoplasm recurrence, in 3 cases we obtained true negative results and in 1 case a false negative image; in 2 cases (7.4%) we found a second malignancy. All patients needed to change the treatment strategies.\r\nConclusion. The significant increase of the number of DTC and the more aggressive behaviour of the disease in some situations, determines the existence of a clear strategy of\r\ntreatment and monitoring, where the role of PET/CT is well defined.
  • Endocrine Care

    Saftencu M, Barbus E, Pestean C, Piciu A, Piciu D

    Evaluation of Cardiovascular Risk and Myocardial Perfusion in Patients with Radically Treated Differentiated Thyroid Carcinoma and Repeated Episodes of Iatrogenic Hypothyroidism

    Acta Endo (Buc) 2016 12(1): 30-34 doi: 10.4183/aeb.2016.30

    Abstract
    Context. Patients with radically treated differentiated thyroid carcinoma (DTC) undergo multiple episodes of iatrogenously-acquired hypothyroidism for the oncological follow-up. In some patients, this elevates high-sensitive C-reactive protein (hsCRP), a cardiovascular risk biomarker. Objective. We wanted to determine if there is any correlation between repeated hypothyroidism episodes, elevated hsCRP and an increased cardiovascular risk as stated through myocardial perfusion. Design. Between July 2014-January 2015, we analyzed serological levels of hsCRP for identifying our patients’ cardiovascular risk; we performed a myocardial perfusion scintigraphy to observe the alterations. Subjects and Methods. We included 27 patients (n=27), mean age of 52±10: CI (95%),14 female, all diseasefree after thyroidectomy, radioiodine ablation and chronic thyroid hormone treatment. We assigned the cardiovascular risk category for each patient according to hsCRP levels; all patients underwent a myocardial perfusion scintigraphy in order to determine the cardiac perfusion index (CPI). Results. hsCRP has been higher in > 65 years old male patients with more than 5 thyroid hormone withholdings. hsCRP is significantly associated with CPI (p=0.001). Spearman’s rank correlation indicates a strongly positive linear correlation between these two parameters (r=0.745). Conclusions. Repeated thyroid hormonal withdrawals in patients with DTC during the long-term follow-up elevated hsCRP at cardiovascular risk levels, having an impact on myocardial perfusion.
  • Notes & Comments

    Piciu D, Irimie A

    Diagnosis and treatment guidlines in thyroid carcinoma. American and European consensus, adapted to Romania

    Acta Endo (Buc) 2007 3(1): 103-115 doi: 10.4183/aeb.2007.103

    Abstract
    The optimization of the diagnosis and therapy strategies, and also their standardization represent a continuous activity of the professional societies. The aim of the study is to review the data from the literature, regarding the thyroid cancer guidelines and to propose a national consensus, especially for differentiated thyroid cancers. There were analyzed the guidelines of diagnosis and treatment for thyroid nodules and thyroid cancer published by the European and American Thyroid Associations (ETA, ATA), by British Thyroid Association, American Association of Clinical Endocrinologist (AACE) and endocrine surgeons (AAES), by European Association of Nuclear Medicine (EANM) and American and European Societies of Clinical Oncology (ASCO and ESMO). We studied the national cancer registry, the institutional cancer registry and the database of nuclear medicine departments from Romania, regarding the limits and instruments as are registered at the National Nuclear Committee. The significant increase of the incidence of thyroid cancer and of the epidemiological data concerning the high percentage of clinically and ultrasoundly detected thyroid nodules, requires a debate around a consensus for the diagnosis and treatment of the differentiated thyroid carcinoma.
  • Case Report

    Piciu A, Cainap C, Sur D, Havasi A, Fetica B, Balacescu O, Mester A, Cainap S

    Rare Malignant Female Adnexal Tumor of Wolffian Origin (Fatwo) with Multiple Relapses and Chemotherapy Regimens

    Acta Endo (Buc) 2021 17(2): 158-164 doi: 10.4183/aeb.2021.158

    Abstract
    Context. Female adnexal tumors of probable Wolffian origin (FATWO) represent very rare borderline ovarian tumors with low malignant potential. Only 15 cases of malignant FATWO are described in the current literature, among which, only 5 are reported as being recurrent. Objective. Due to the rare presentation of the recurrence of the malignant FATWO and the few cases reported in the scientific database, there are no clear therapy recommendations. This paper should help practitioners to choose the best therapy approach. Design. This paper presents the 6th case of malignant recurrent FATWO and will compare all the cases available in the literature. Subjects and Methods. We present a review of the literature comparing the therapeutic approaches and outcomes of all the five cases of recurrent malignant FATWOs. Also, we introduce the case of a stage III Wolffian origin adnexal tumor with multiple recurrences appeared after 6 years of disease free interval. Results. Our case presents the longest survival reported in the literature and underwent most surgical procedures of the recurrences and more than 4 lines of chemotherapy regimens. Conclusions. This paper shows possible therapeutic approaches to be used as example by the practitioners according to the drug availability in their centers.
  • Endocrine Care

    Badulescu CI, Piciu D, Apostu D, Badan M, Piciu A

    Follicular Thyroid Carcinoma - Clinical and Diagnostic Findings in a 20-Year Follow Up Study

    Acta Endo (Buc) 2020 16(2): 170-177 doi: 10.4183/aeb.2020.170

    Abstract
    Context. Follicular thyroid carcinomas (FTC) represent 6-10 % of all thyroid carcinomas; the evolution of FTC is quite controversial, partly due to frequent changes of the histopathological definition (minimally invasive–MIFTC or widely invasive carcinoma–WIFTC) and treatment strategies adjustments. Objective. This research aims to examine the diagnostic procedure, therapeutic attitude and survival rates of patients with FTC, over a period of 16 years in the same institution, with a follow-up of at least 4 years, by analyzing correlations between histology subtype, treatments and the rate of recurrent disease. Subjects and methods. We have studied 5891 patients with thyroid carcinomas who have undergone surgical or oncological treatment within the institution, between 1st January 2000 – 31st December 2015; among them we found 133 patients (2.25%) with “pure” follicular thyroid carcinoma: 114 (86%) women and 19 (14%) men, with a female-male ratio of 6:1. The age of the patients ranged from 10 to 76 years, with an average of 47.8 years. Statistical analysis was done comparing differences among groups of MIFTC and WIFTC. Results. There was an unexpected high percentage of WIFTC and also an increased number of biochemically persistent and/or recurrent disease in patients with MIFTC. A stronger correlation was observed with the tumour dimensions, rather than with the histopathological subtype. Conclusions. This research observed that overall survival was associated with tumour size rather than histopathological subtype and there is an important need to perform further studies to assess the effectiveness of treatment strategies.
  • Endocrine Care

    Larg MI, Barbus E, Gabora K, Pestean C, Cheptea M, Piciu D

    18F-FDG PET/CT in Differentiated Thyroid Carcinoma

    Acta Endo (Buc) 2019 15(2): 203-208 doi: 10.4183/aeb.2019.203

    Abstract
    Aim. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) become an important tool in oncology by combining the metabolic information from 18F-FDG PET with the morphological information of CT. The main objective of this study was to assess the diagnostic value of PET/CT in patients with differentiated thyroid carcinoma (DTC). Material and Methods. We analyzed 173 PET/CT scans of patients with DTC presenting elevated thyroglobulin (Tg) levels, negative Tg-antibodies levels, negative Iodine-131 whole-body scanning (I-131 WBS) and without any signs of clinical or other imaging technique for tumor recurrence/metastases. Results. PET/CT scans were positive in 38% of cases (65/173). The sensitivity, specificity, positive predictive values and the accuracy of PET/CT imaging were 88.09%, 98.6%, 93.1% respectively 96.53%. After the PET/CT scan 29 patients underwent surgery, 24 of them continued radio-iodine therapy, 5 patients initiated tyrosine kinase inhibitors treatment and external radiotherapy. Conclusion. 18F-FDG PET/CT is a valuable imaging technique which has the capability of identifying those cases of thyroid recurrence/metastases with elevated Tg levels and negative I-131 WBS. The treatment strategy was changed in 89.2% cases of positive PET/CT scans which shows us that 18F-FDG PET/CT imaging should be integrated into the follow-up programs for DTC patients.
  • Images in Endocrinology

    Piciu D, Larg MI, Barbus E, Piciu A

    Unusual Peritoneal and Muscular Metastases in an Aggressive and Extensive Case of Anaplastic Thyroid Cancer on 18F-FDG PET/CT

    Acta Endo (Buc) 2018 14(3): 408-409 doi: 10.4183/aeb.2018.408

  • Images in Endocrinology

    Piciu D, Pestean C, Bara A, Moisescu C, Roman A

    Optimistic left hemithorax 131I uptake in a thyroid cancer patient

    Acta Endo (Buc) 2009 5(3): 417-417 doi: 10.4183/aeb.2009.417

  • Images in Endocrinology

    Piciu D, Piciu A, Irimie A

    Cerebral False-Positive Radioiodine Uptake

    Acta Endo (Buc) 2012 8(3): 495-495 doi: 10.4183/aeb.2012.495